• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于绿色 Raji 单位 (GRU) 剂量的人源化小鼠 EBV 感染的剂量依赖性结果。

Dose-Dependent Outcome of EBV Infection of Humanized Mice Based on Green Raji Unit (GRU) Doses.

机构信息

State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.

State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, School of Life Sciences, Xiamen University, Xiamen 361005, China.

出版信息

Viruses. 2021 Oct 29;13(11):2184. doi: 10.3390/v13112184.

DOI:10.3390/v13112184
PMID:34834989
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8624110/
Abstract

Humanized mouse models are used as comprehensive small-animal models of EBV infection. Previously, infectious doses of EBV used in vivo have been determined mainly on the basis of TD (50% transforming dose), which is a time-consuming process. Here, we determined infectious doses of Akata-EBV-GFP using green Raji units (GRUs), and characterized dose-dependent effects in humanized mice. We defined two outcomes in vivo, including an infection model and a lymphoma model, following inoculation with low or high doses of Akata-EBV-GFP, respectively. Inoculation with a low dose induced primary B cells to become lymphoblastoid cell lines in vitro, and caused latent infection in humanized mice. In contrast, a high dose of Akata-EBV-GFP resulted in primary B cells death in vitro, and fatal B cell lymphomas in vivo. Following infection with high doses, the frequency of CD19 B cells decreased, whereas the percentage of CD8 T cells increased in peripheral blood and the spleen. At such doses, a small part of activated CD8 T cells was EBV-specific CD8 T cells. Thus, GRUs quantitation of Akata-EBV-GFP is an effective way to quantify infectious doses to study pathologies, immune response, and to assess (in vivo) the neutralizing activity of antibodies raised by immunization against EBV.

摘要

人源化小鼠模型被用作 EBV 感染的综合小动物模型。此前,体内使用的 EBV 感染剂量主要基于 TD(50%转化剂量)来确定,这是一个耗时的过程。在这里,我们使用绿色 Raji 单位 (GRU) 确定了 Akata-EBV-GFP 的感染剂量,并对人源化小鼠中的剂量依赖性效应进行了特征描述。我们定义了两种体内结果,分别为低剂量和高剂量接种 Akata-EBV-GFP 后诱导的感染模型和淋巴瘤模型。低剂量接种可诱导原代 B 细胞在体外成为淋巴母细胞系,并在人源化小鼠中引起潜伏感染。相比之下,高剂量的 Akata-EBV-GFP 可导致原代 B 细胞在体外死亡,并导致体内致命的 B 细胞淋巴瘤。高剂量感染后,外周血和脾脏中 CD19 B 细胞的频率降低,而 CD8 T 细胞的百分比增加。在这些剂量下,一小部分活化的 CD8 T 细胞是 EBV 特异性 CD8 T 细胞。因此,Akata-EBV-GFP 的 GRU 定量是一种有效确定感染剂量的方法,可用于研究病理学、免疫反应,并评估针对 EBV 免疫接种产生的抗体的中和活性(体内)。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5eb/8624110/08e591c2bc05/viruses-13-02184-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5eb/8624110/defd3bd58696/viruses-13-02184-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5eb/8624110/5bfd452fc407/viruses-13-02184-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5eb/8624110/71cce3d36e7b/viruses-13-02184-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5eb/8624110/7562a565cc4f/viruses-13-02184-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5eb/8624110/08e591c2bc05/viruses-13-02184-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5eb/8624110/defd3bd58696/viruses-13-02184-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5eb/8624110/5bfd452fc407/viruses-13-02184-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5eb/8624110/71cce3d36e7b/viruses-13-02184-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5eb/8624110/7562a565cc4f/viruses-13-02184-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c5eb/8624110/08e591c2bc05/viruses-13-02184-g005.jpg

相似文献

1
Dose-Dependent Outcome of EBV Infection of Humanized Mice Based on Green Raji Unit (GRU) Doses.基于绿色 Raji 单位 (GRU) 剂量的人源化小鼠 EBV 感染的剂量依赖性结果。
Viruses. 2021 Oct 29;13(11):2184. doi: 10.3390/v13112184.
2
Epstein-Barr Virus Type 2 Infects T Cells and Induces B Cell Lymphomagenesis in Humanized Mice.EBV 型 2 感染 T 细胞并在人源化小鼠中诱导 B 细胞淋巴瘤发生。
J Virol. 2018 Oct 12;92(21). doi: 10.1128/JVI.00813-18. Print 2018 Nov 1.
3
MicroRNAs of Epstein-Barr Virus Attenuate T-Cell-Mediated Immune Control .EB 病毒微小 RNA 减弱 T 细胞介导的免疫控制
mBio. 2019 Jan 15;10(1):e01941-18. doi: 10.1128/mBio.01941-18.
4
PD-1/CTLA-4 Blockade Inhibits Epstein-Barr Virus-Induced Lymphoma Growth in a Cord Blood Humanized-Mouse Model.PD-1/CTLA-4阻断在脐血人源化小鼠模型中抑制爱泼斯坦-巴尔病毒诱导的淋巴瘤生长。
PLoS Pathog. 2016 May 17;12(5):e1005642. doi: 10.1371/journal.ppat.1005642. eCollection 2016 May.
5
A new humanized mouse model of Epstein-Barr virus infection that reproduces persistent infection, lymphoproliferative disorder, and cell-mediated and humoral immune responses.一种新的爱泼斯坦-巴尔病毒感染的人源化小鼠模型,该模型可重现持续性感染、淋巴增殖性疾病以及细胞介导和体液免疫反应。
J Infect Dis. 2008 Sep 1;198(5):673-82. doi: 10.1086/590502.
6
Spatiotemporally Skewed Activation of Programmed Cell Death Receptor 1-Positive T Cells after Epstein-Barr Virus Infection and Tumor Development in Long-Term Fully Humanized Mice.EB 病毒感染及肿瘤发生后,长期完全人源化小鼠中程序性细胞死亡受体 1 阳性 T 细胞的时空偏激活
Am J Pathol. 2019 Mar;189(3):521-539. doi: 10.1016/j.ajpath.2018.11.014. Epub 2018 Dec 26.
7
Adoptive transfer of EBV specific CD8+ T cell clones can transiently control EBV infection in humanized mice.EBV特异性CD8 + T细胞克隆的过继转移可暂时控制人源化小鼠中的EBV感染。
PLoS Pathog. 2014 Aug 28;10(8):e1004333. doi: 10.1371/journal.ppat.1004333. eCollection 2014 Aug.
8
T cell-mediated control of Epstein-Barr virus infection in humanized mice.人源化小鼠中T细胞介导的对爱泼斯坦-巴尔病毒感染的控制
J Infect Dis. 2009 Nov 15;200(10):1611-5. doi: 10.1086/644644.
9
Experimental infection of NOD/SCID mice reconstituted with human CD34+ cells with Epstein-Barr virus.用人CD34+细胞重建的NOD/SCID小鼠感染爱泼斯坦-巴尔病毒的实验性感染。
J Virol. 2004 Dec;78(24):13891-900. doi: 10.1128/JVI.78.24.13891-13900.2004.
10
Studying Epstein-Barr virus pathologies and immune surveillance by reconstructing EBV infection in mice.通过在小鼠体内重建EB病毒感染来研究EB病毒病理学和免疫监测。
Cold Spring Harb Symp Quant Biol. 2013;78:259-63. doi: 10.1101/sqb.2013.78.020222. Epub 2013 Nov 15.

引用本文的文献

1
A cocktail nanovaccine targeting key entry glycoproteins elicits high neutralizing antibody levels against EBV infection.针对关键进入糖蛋白的鸡尾酒纳米疫苗引发了针对 EBV 感染的高中和抗体水平。
Nat Commun. 2024 Jun 21;15(1):5310. doi: 10.1038/s41467-024-49546-w.
2
Neutralizing antibodies against EBV gp42 show potent protection and define novel epitopes.针对 EBV gp42 的中和抗体显示出强大的保护作用,并定义了新的表位。
Emerg Microbes Infect. 2023 Dec;12(2):2245920. doi: 10.1080/22221751.2023.2245920.
3
Urgency and necessity of Epstein-Barr virus prophylactic vaccines.

本文引用的文献

1
T cell epitope screening of Epstein-Barr virus fusion protein gB.爱泼斯坦-巴尔病毒融合蛋白gB的T细胞表位筛选
J Virol. 2021 Apr 26;95(10). doi: 10.1128/JVI.00081-21. Epub 2021 Mar 3.
2
PD-1 Blockade Aggravates Epstein-Barr Virus Post-Transplant Lymphoproliferative Disorder in Humanized Mice Resulting in Central Nervous System Involvement and CD4 T Cell Dysregulations.程序性死亡蛋白1(PD-1)阻断加重人源化小鼠移植后EB病毒淋巴增殖性疾病,导致中枢神经系统受累和CD4 T细胞失调。
Front Oncol. 2021 Jan 12;10:614876. doi: 10.3389/fonc.2020.614876. eCollection 2020.
3
CAR-T Cells Targeting Epstein-Barr Virus gp350 Validated in a Humanized Mouse Model of EBV Infection and Lymphoproliferative Disease.
爱泼斯坦-巴尔病毒预防性疫苗的紧迫性和必要性。
NPJ Vaccines. 2022 Dec 9;7(1):159. doi: 10.1038/s41541-022-00587-6.
4
What do animal models tell us about the role of EBV in the pathogenesis of multiple sclerosis?动物模型向我们揭示了 EBV 在多发性硬化症发病机制中的作用吗?
Front Immunol. 2022 Nov 17;13:1036155. doi: 10.3389/fimmu.2022.1036155. eCollection 2022.
5
Glycoprotein B Antibodies Completely Neutralize EBV Infection of B Cells.糖蛋白 B 抗体可完全中和 EBV 对 B 细胞的感染。
Front Immunol. 2022 May 27;13:920467. doi: 10.3389/fimmu.2022.920467. eCollection 2022.
6
Vesicular Stomatitis Virus-Based Epstein-Barr Virus Vaccines Elicit Strong Protective Immune Responses.基于水疱性口炎病毒的 Epstein-Barr 病毒疫苗可诱导强烈的保护性免疫应答。
J Virol. 2022 May 11;96(9):e0033622. doi: 10.1128/jvi.00336-22. Epub 2022 Apr 11.
靶向爱泼斯坦-巴尔病毒gp350的嵌合抗原受体T细胞在EBV感染和淋巴细胞增殖性疾病的人源化小鼠模型中得到验证。
Mol Ther Oncolytics. 2020 Aug 8;18:504-524. doi: 10.1016/j.omto.2020.08.005. eCollection 2020 Sep 25.
4
Neutralizing Antibodies Protect against Oral Transmission of Lymphocryptovirus.中和抗体可预防淋巴脉络丛病毒的经口传播。
Cell Rep Med. 2020 Jun 23;1(3). doi: 10.1016/j.xcrm.2020.100033.
5
A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection.一种基于嵌合病毒样颗粒展示多个保守表位肽的新型候选疫苗诱导了针对 EBV 感染的中和抗体。
Theranostics. 2020 Apr 27;10(13):5704-5718. doi: 10.7150/thno.42494. eCollection 2020.
6
Immune Control and Vaccination against the Epstein-Barr Virus in Humanized Mice.人源化小鼠中针对爱泼斯坦-巴尔病毒的免疫控制与疫苗接种
Vaccines (Basel). 2019 Dec 17;7(4):217. doi: 10.3390/vaccines7040217.
7
Vasculogenic mimicry formation in EBV-associated epithelial malignancies.EBV 相关上皮性恶性肿瘤中的血管生成拟态形成。
Nat Commun. 2018 Nov 27;9(1):5009. doi: 10.1038/s41467-018-07308-5.
8
Epstein-Barr virus activates F-box protein FBXO2 to limit viral infectivity by targeting glycoprotein B for degradation. Epstein-Barr 病毒激活 F-box 蛋白 FBXO2 ,通过靶向糖蛋白 B 进行降解来限制病毒感染力。
PLoS Pathog. 2018 Jul 27;14(7):e1007208. doi: 10.1371/journal.ppat.1007208. eCollection 2018 Jul.
9
Establishment of EBV-Infected Lymphoblastoid Cell Lines.爱泼斯坦-巴尔病毒感染的淋巴母细胞系的建立。
Methods Mol Biol. 2017;1532:57-64. doi: 10.1007/978-1-4939-6655-4_3.
10
PD-1/CTLA-4 Blockade Inhibits Epstein-Barr Virus-Induced Lymphoma Growth in a Cord Blood Humanized-Mouse Model.PD-1/CTLA-4阻断在脐血人源化小鼠模型中抑制爱泼斯坦-巴尔病毒诱导的淋巴瘤生长。
PLoS Pathog. 2016 May 17;12(5):e1005642. doi: 10.1371/journal.ppat.1005642. eCollection 2016 May.